Advertisement

The effects of intrathecal ketanserin and phentolamine on heart rate and arterial blood pressure in the rat

  • K. Mohan Dhasmana
  • Ajay K. Banerjee
  • Pramod R. Saxena
Chapter
Part of the Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine book series (DICM, volume 106)

Abstract

Ketanserin lowers arterial blood pressure in both animals and humans, but the mechanism of its antihypertensive action is in debate [see 1]. In general, it is now accepted that ketanserin, at least partly, lowers blood pressure by α 1-adrenoceptor blockade [2–4]. However, additional mechanisms, such as the blockade of 5-HT2 receptor-mediated amplification of the vasoconstrictor action of noradrenaline by 5-hydroxytryptamine (5-HT) [see 5], direct vasodilatation [4] and a CNS action [6–8], have also recently been implicated. In this investigation the effects of intrathecal administration of ketanserin and phentolamine on arterial blood pressure and heart rate in normotensive anaesthetized rats have been studied.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Saxena PR, Bolt GR, Dhasmana KM (1987): Serotonin agonists and antagonists in experimental hypertension. J Cardiovasc Pharmacol 10 (suppl. 3): S12–S18.CrossRefGoogle Scholar
  2. 2.
    Fozard JR (1982): Mechanism of the hypotensive effect of ketanserin. J Cardiovasc Pharmacol 4: 829–838.PubMedCrossRefGoogle Scholar
  3. 3.
    Kalkman HO, Timmermans PBMWM, Van Zwieten PA (1982): Characterization of the antihypertensive properties of ketanserin (R 41486) in rats. J Pharmacol Exp Ther 22: 227–231.Google Scholar
  4. 4.
    Bolt GR, Saxena PR (1985): Cardiovascular profile and hypotensive mechanism of ketanserin in the rabbit. Hypertension 7: 499–506.PubMedCrossRefGoogle Scholar
  5. 5.
    Vanhoutte PM, Amery A, Birkenhäger W, Breckenridge A, Bühler F, Distler A, Dormandy J, Doyle A, Frohlich E, Hansson L, Hedner T, Hollenberg N, Jensen H-E, Lund-Johansen P, Meyer P, Opie L, Robertson I, Safar M, Schalekamp M, Symoens J, Trap-Jensen J, Zanchetti A (1988): Serotonergic mechanisms in hypertension: Focus on the effects of ketanserin. Hypertension 11: 111–133.PubMedCrossRefGoogle Scholar
  6. 6.
    McCall RB, Schuette MR (1984): Evidence for an alpha-1 receptor-mediated central sympathoinhibitory action of ketanserin. J Pharmacol Exp Ther 228: 704–710.PubMedGoogle Scholar
  7. 7.
    Mylecharane EJ, Phillips CA, Markus JK, Show J (1985): Evidence for a central component to the hypotensive action of ketanserin in the dog. J Cardiovasc Pharmacol 7: 514–516.CrossRefGoogle Scholar
  8. 8.
    Van Zwieten PA, Mathy MJ, Boddeke HWGM, Doods HN (1987): Central hypotensive activity of ketanserin in cats. J Cardiovasc Pharmacol 10 (suppl. 3): S54–S58.CrossRefGoogle Scholar
  9. 9.
    Yaksh TL, Rudy TA (1976): Chronic catheterization of the spinal subarachnoid space. Physiol Behav 17: 1031–1036.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1990

Authors and Affiliations

  • K. Mohan Dhasmana
  • Ajay K. Banerjee
  • Pramod R. Saxena

There are no affiliations available

Personalised recommendations